Should meropenem be replaced with ceftazidime‑avibactam plus aztreonam in a 27‑year‑old male with severe meningoencephalitis, recurrent seizures, Glasgow Coma Scale 6, persistent leptomeningeal enhancement, marked leukocytosis and elevated procalcitonin who is already receiving vancomycin, dexamethasone, mannitol and empirical four‑drug anti‑tubercular therapy?

Do Not Switch to Ceftazidime-Avibactam Plus Aztreonam

Continue meropenem for this critically ill patient with severe meningoencephalitis, as meropenem remains the evidence-based first-line agent for bacterial meningitis with proven CNS penetration and efficacy, whereas ceftazidime-avibactam plus aztreonam should be reserved specifically for documented carbapenem-resistant or metallo-β-lactamase-producing organisms.

Rationale for Continuing Meropenem

Meropenem is FDA-Approved for Bacterial Meningitis

• Meropenem has specific FDA approval for bacterial meningitis in pediatric patients ≥3 months at 40 mg/kg every 8 hours (maximum 2 grams) 1
• Clinical trials demonstrated 100% clinical cure rate in evaluable adult meningitis patients treated with meropenem versus 77% with third-generation cephalosporins 2
• Meropenem achieved excellent CSF penetration and eradicated all pre-treatment isolates except one S. aureus in a comparator-treated patient 2
• No seizures occurred after therapy initiation despite high doses (6 g/day) and underlying CNS disorders 2

Ceftazidime-Avibactam Plus Aztreonam Has No Meningitis Indication

The combination is specifically indicated only for carbapenem-resistant Enterobacterales (CRE) infections, particularly those producing metallo-β-lactamases 3:

• Guidelines recommend this combination for documented metallo-β-lactamase-producing CRE with 30-day mortality of 19.2% versus 44% with other agents (HR 0.37,95% CI 0.13-0.74) 3
• The evidence base consists of bloodstream infections, intra-abdominal infections, and hospital-acquired pneumonia—not meningitis 3, 4
• CSF penetration data for ceftazidime-avibactam in meningitis are extremely limited

When to Consider the Switch

Only switch if microbiological data confirm:

1. Carbapenem-resistant organism (MIC >8 mg/L to meropenem)
2. Metallo-β-lactamase production (NDM, VIM, IMP) documented by molecular testing
3. Clinical failure after 48-72 hours of adequate meropenem therapy

Critical Implementation Points

The 2023 guidelines explicitly state: "the carbapenemase type produced by CRE strain should be ascertained before initiation of ceftazidime-avibactam treatment, whenever possible" 3

Case Reports Support Targeted Use Only

Recent case reports demonstrate successful use of ceftazidime-avibactam plus aztreonam for documented NDM-producing Klebsiella pneumoniae CNS infections 5, 6:

• A 61-year-old with post-neurosurgical infection initially failed ceftazidime-avibactam monotherapy because repeat testing revealed dual KPC+NDM production 5
• Success required simultaneous intravenous ceftazidime-avibactam and aztreonam plus topical polymyxin B irrigation 5
• Another case used the combination only after confirming MDR Klebsiella with documented resistance patterns 6

Key lesson: These cases succeeded because they were culture-directed therapy for proven resistant organisms, not empirical switches.

Current Clinical Context

Your patient has:

• Marked leukocytosis and elevated procalcitonin suggesting active bacterial infection
• Already receiving vancomycin for Gram-positive coverage
• Empirical anti-tubercular therapy addressing alternative diagnoses
• No documented carbapenem resistance

The Risk of Premature Switching

Switching without documented resistance:

• Wastes a last-line agent needed for true carbapenem-resistant infections
• Lacks evidence for meningitis treatment
• Violates antimicrobial stewardship principles 3, 7
• May have inferior CNS penetration compared to meropenem

Recommended Approach

Continue current regimen and obtain:

1. CSF cultures with carbapenemase testing (PCR for KPC, NDM, OXA-48, VIM)
2. Meropenem MIC determination if organism isolated
3. Clinical reassessment at 48-72 hours for fever curve, GCS improvement, seizure control

Switch to ceftazidime-avibactam plus aztreonam only if:

• Cultures grow carbapenem-resistant organism (meropenem MIC >8 mg/L)
• Molecular testing confirms metallo-β-lactamase production
• Clinical deterioration despite adequate meropenem levels

Dosing if Switch Required

Based on case reports 5, 6:

• Ceftazidime-avibactam 2.5 g IV every 8 hours
• Aztreonam 2 g IV every 8 hours
• Consider adjunctive intrathecal/intraventricular polymyxin if external drainage present

The 2022 ESCMID guidelines support this conservative approach: "For patients with CRE infections susceptible to and treated with ceftazidime-avibactam, meropenem-vaborbactam or cefiderocol, we do not recommend combination therapy" 7—implying these agents should be reserved for documented resistance, not used empirically.